Kazia Therapeutics (KZIA) Receivables - Accured (2016)

Kazia Therapeutics (KZIA) posted Receivables - Accured of -$750.16 for Q4 2016, little changed on a QoQ basis from -$746.7 in Q2 2016.

Kazia Therapeutics (KZIA) Receivables - Accured (2016) Analysis & Trends

Kazia Therapeutics' Receivables - Accured history runs 1 years deep, the most recent figure standing at -$750.16 for Q4 2016.

Quarterly Receivables - Accured changed N/A year-over-year to -$750.16 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$750.16 (changed N/A YoY) and the FY2016 annual result came in at -$750.16, changed N/A from the prior year.
Receivables - Accured was -$750.16 for Q4 2016 at Kazia Therapeutics, roughly flat from -$746.7 in the prior quarter.
Across five years, Receivables - Accured topped out at -$746.7 in Q2 2016 and bottomed at -$750.16 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Kazia Therapeutics	4.11 Mn	4.11 Mn	-	-

Download Data